TrialEBioMedicine2025

Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.

Lisanne A H Bevers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.